Possibilities for early diagnosis of contrast-induced nephropathy

DOI: https://doi.org/10.29296/25877305-2019-10-03
Download full text PDF
Issue: 
10
Year: 
2019

M. Shonia, Candidate of Medical Sciences; Yu. Khalturina, Candidate of Medical Sciences; Yu. Paramonova, Candidate of Medical Sciences; D. Pivovarov; A. Pivovarova Volga Research Medical University, Nizhny Novgorod

The primary excretory organ in the human body is the kidney; it is the latter that is involved in the excretion of substances used for treatment and diagnosis. The list of potentially nephrotoxic drugs is extensive and is growing as novel pharmacological agents are being designed. A special place is given to contrast-induced nephropathy among the toxic kidney damages. This pathology is an important clinical problem that develops in parallel with the widespread use of diagnostic and therapeutic procedures using contrast agents, since the main way for their elimination is through the kidneys.
Keywords: 
nephrology
contrast-induced nephropathy
radiopaque agents
coronarography
nephrotoxicity
biomarkers
nephrin
cystatin C
lipocalin-2/NGAL

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Klinicheskie rekomendatsii po profilaktike, diagnostike i lecheniju kontrast-indutsirovannoj nefropatii, 2012. [Clinical recommendations for the prevention, diagnosis and treatment of contrast-induced nephropathy, 2012 (in Russ.)].
  2. Turenko O.I., Lebedeva A.Ju., Gordeev I.G. i dr. Problema kontrastindutsirovannoj nefropatii v kardiologii// Ros. kardiol. zhurn. – 2011; 3 (89): 78–86 [Turenko O.I., Lebedeva A.Y., Gordeev I.G. et al. Contrast-induced nephropathy in cardiology practice // Russian Journal of Cardiology. – 2011; 3 (89): 78–86 (in Russ.)]. https://doi.org/10.15829/1560-4071-2011-3-78-86.
  3. Sandler C. Contrast-agent-induced acute renal dysfunction – is iodixanol the answer? // N. Engl. J. Med. – 2008; 348 (6): 551–3. DOI: 10.1056/NEJMe020183.
  4. KDIGO 2012 clinical practice guideline for acute kidney injury // Kidney Int. – 2012; 2 (Suppl. 1): 1–141.
  5. Chong E., Poh K., Liang S. et al. Risk factors and clinical outcomes for contrast – induced nephropathy after percutaneous coronary interventions in patients with normal serum creatinine // Ann. Acad. Med. Singapore. – 2010; 39 (5): 374–80.
  6. Karlsberg R., Dohad S., Sheng R. Contrast-induced acute kidney injury (CI-AKI) following intra-arterial administration of iodinated contrast media // J. Nephrol. – 2010; 23 (6): 658–66.
  7. Radovanovic D., Urban P., Simon R. et al. Outcome of patients with acute coronary syndrome in hospitals of different sizes. A report from the AMIS Plus Registry // Swiss Med. Wkly. – 2010; 140 (21–22): 314–22. DOI: smw-12986.
  8. Vel'kov V.V., Reznikova O.I. Sovremennaja laboratornaja diagnostika renal'nyh patologij: ot rannih stadij do ostroj pochechnoj nedostatochnosti // Sovremennye laboratornye testy: novye tehnologii i klinicheskaja znachimost'. – 2014; 12 (2): 26–9 [Vel’kov V.V., Reznikova O.I. Sovremennaya laboratornaya diagnostika renal’nykh patologii: ot rannikh stadii do ostroi pochechnoi nedostatochnosti // Sovremennye laboratornye testy: novye tekhnologii i klinicheskaya znachimost’. – 2014; 12 (2): 26– 9 (in Russ.)].
  9. Bartorelli A., Marenzi G. Contrast – induced nephropathy // J. Interv. Cardiol. – 2009; 3: 13. DOI: 10.1111/j.1540-8183.2007.00318.x.
  10. Kiseleva O.A., Usenko A.N., Sidorova E.E. i dr. Deformatsionnye svojstva eritrotsitov cheloveka v prisutstvii rentgenokontrastnyh sredstv // Eksperim. i klin. farmakol. – 2009; 72: 33–5 [Kiseleva O.A.1, Usenko A.N.1, Sidorova E.E. et al. Deformation properties of human erythrocytes in the presence of x-ray contrast agents // Eksperim. i klin. farmakol. – 2009; 72: 33–5 (in Russ.)].
  11. Shimanovskij N.L. Kontrastnye sredstva: rukovodstvo po ratsional'nomu primeneniju / M.: GEOTAR-Media, 2009; 104–47 [Shimanovskii N.L. Kontrastnye sredstva: rukovodstvo po ratsional’nomu primeneniyu / M.: GEOTAR-Media, 2009; 104–47 (in Russ.)].
  12. Volgina G.V. Kontrast-indutsirovannaja nefropatija: patogenez, faktory riska, strategija profilaktiki (chast' II) // Nefrologija i dializ. – 2006; 8 (2): 176–83 [Volgina G.V. Contrast-induced nephropathy: pathogenesis, risk factors, prevention strategies (Part II) // Nefrologiya i dializ. – 2006; 8 (2): 176–83 (in Russ.)].
  13. Jarkova N.A., Borovkov N.N. Algoritm rannej diagnostiki kontrast-indutsirovannoj nefropatii s ispol'zovaniem biomarkerov pochechnogo povrezhdenija // Sovremennye tehnologii v meditsine. – 2017; 9 (4): 156–61 [Yarkova N.A., Borovkov N.N. Algorithm for Early Diagnosis of Contrast-Induced Nephropathy Using Biomarkers of Renal Damage // Sovremennye tekhnologii v meditsine. – 2017; 9 (4): 156–61 (in Russ.)]. DOI: 10.17691/stm2017.9.4.19.
  14. Heinrich M., Häberle L., Müller V. et al. Nephrotoxicity of isoosmolar iodixanol compared with nonionic low-osmolar contrast media: metaanalysis of randomized controlled trials // Radiology. – 2009; 250 (1): 68–86. DOI: 10.1148/radiol.2501080833.
  15. Mironova O.Ju. Indutsirovannaja kontrastnymi veschestvami nefropatija // Ter. arh. – 2013; 85 (6): 90–5 [Mironova O.Yu. Contrast-induced nephropathy // Ter. arkh. – 2013; 85 (6): 90–5 (in Russ.)].
  16. McCullough P., Adam A., Becker C. et al. Risk prediction of contrastinduced nephropathy // Am. J. Cardiol. – 2006; 98 (6): 27–36. DOI: 10.1016/j.amjcard.2006.01.022.
  17. Rudnick M., Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? // Clin. J. Am. Soc. Nephrol. – 2008; 3 (1): 263–72. DOI: 10.2215/cjn.03690907.
  18. Marenzi G., Assaneli E., Campodonico J. et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast – induced nephropathy and mortality // Ann. Intern. Med. – 2009; 150: 170–7.
  19. Solomon R., Mehran R., Natarajan M. et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? // Clin. J. Am. Soc. Nephrol. – 2009; 4 (7): 1162–9. DOI: 10.2215/CJN.00550109.
  20. Aspelin P., Aubry P., Fransson S. et al. Nephrotoxic effects in high-risk patients undergoing angiography // N. Engl. Med. – 2009; 348: 491–9. DOI: 10.1056/NEJMoa021833.
  21. Jarkova N.A., Moskovtseva O.M., Zav'jalova Ju.V. Tsistatin S, nefrin, lipokalin-2: znachenie dlja rannej diagnostiki kontrast-indutsirovannogo povrezhdenija pochek u patsientov s saharnym diabetom 2-go tipa // Med. al'manah. – 2018; 6: 137–40 [Yarkova N.A., Moskovtseva O.M., Zavialova Y.V. Cystatin C, nephrin, lipocalin-2: importance of early diagnosing contrast-induced acute kidney damage in patients with type 2 diabetes mellitus // Medical Almanac. – 2018; 6: 137–40 (in Russ.)]. https://doi.org/10.21145/2499-9954-2018-6-137-140.
  22. Dil'dabekova A.S. Tsistatin S v diagnostike ostryh i hronicheskih povrezhdenij pochek // Mezhdunarodnyj zhurnal prikladnyh i fundamental'nyh issledovanij. – 2016; 11 (1): 66–70 [Dildabekova A.S. Cystatin C in diagnosis of acute and chronic kidney injury // International Journal of Applied and Fundamental Research. – 2016. 11(1): 66–70 (in Russ.)].
  23. Jarkova N.A., Borovkov N.N., Zanozina O.V. i dr. Tsistatin S v diagnostike hronicheskoj bolezni pochek u bol'nyh saharnym diabetom 2-go tipa // Sovremennye tehnologi v meditsine. – 2013; 5 (4): 89–93 [Yarkova N.A., Borovkov N.N., Zanozina O.V. et al. Cystatin C in the Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus // Sovremennye tekhnologi v meditsine. – 2013; 5 (4): 89–93 (in Russ.)].
  24. Roos J., Doust J., Tett S. et al. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children – a meta-analysis // Clin. Biochem. – 2007; 40 (5–6): 383–91. DOI: 10.1016/j.clinbiochem.2006.10.026.
  25. Grubb A., Björk J., Lindström V. et al. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula // Scand. J. Clin. Lab. Invest. – 2005; 65 (2): 153–62. DOI: 10.1080/00365510510013596.
  26. Jarkova N.A. Nefrin-rannij marker povrezhdenija pochek pri saharnom diabete 2 tipa // Med. al'manah. – 2017; 2 (47): 101–3 [Yarkova N.A. Nephrin – early marker of kidney disorder in the case of diabetes mellitus of the 2nd type // Medical Almanac. – 2017; 65 (2): 101–3 (in Russ.)]. https://doi.org/10.21145/2499-9954-2017-2-101-103.
  27. Dolgov V.V. Immunohimicheskij analiz v laboratornoj meditsine. Pod red. V.V. Dolgova / M., Tver': Triada, 2015; 418 s. [Dolgov V.V. Immunokhimicheskii analiz v laboratornoi meditsine. Pod red. V.V. Dolgova / M., Tver’: Triada, 2015; 418 s. (in Russ.)].
  28. Mishra J. et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury // Clin. J. Am. Soc. Nephrol. – 2003; 14: 2534–43. DOI: 10.1097/01.asn.0000088027.54400.c6.
  29. Mishra J. et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity // Clin. J. Am. Soc. Nephrol. – 2004; 24: 307–15. DOI: 10.1159/000078452.
  30. Grigoryev D., Liu M., Hassoun H. et al. The local and systemic inflammatory transcriptome after acute kidney injury // J. Am. Soc. Nephrol. – 2008; 19 (3): 547–58. DOI: 10.1681/ASN.2007040469.
  31. Schmidt-Ott K. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury--where do we stand today? // Nephrol. Dial. Transplant. – 2011; 26 (3): 762-4. DOI: 10.1093/ndt/gfr006.
  32. Proletov Ja.Ju., Saganova E.S., Galkina O.V. i dr. Rol' nekotoryh biomarkerov v otsenke haraktera pochechnogo povrezhdenija u patsientov s hronicheskimi glomerulopatijami // Nefrologija. – 2013; 17 (1): 60–9 [Proletov Ya.Yu., Saganova E.S., Galkina O.V. et al. The role of several biomarkers in estimation of kidney injury in patients with primary glomerulopathies // Nefrologiya. – 2013; 17 (1): 60–9 (in Russ.)].